08.08.2012 - Pfizer, Johnson & Johnson and Elan will end the development of bapineuzumab. The antibody was thought to become a treatment for Alzheimer's disease with hundreds of millions in sale.
The decision came after the antibody targeting amyloid beta did not meet the co-primary endpoints of change in cognitive and functional performance in a phase III study in patients lacking a mutation in the apolipoprotein E epsilon. The trial was led by J&J's research affiliate Janssen Cilag. Some experts said the result came as no surprise as the window of success was very small. Nevertheless, Bapineuzumab is one of the most advanced antibodies targeting amyloid beta. For Elan's future, the study failure could have a large effect. The company was responsible to pay for 49,9% of the trial costs. That leads to a US-$117.3m non-cash impairment charge in the third quarter of 2012. Elan shares fell more than 12%. Analysts speculated that the the success of bapineuzumab could influence a potential sale of the company, noting that Elan's partner Biogen Idec could step in at the right price.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.